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Gastric cancer is the fourth most commonly diragnosed cancer and the second leading cause of cancer deaths worldwide.1 Patients with 
gastric cancer typically present with advanced disease 
and it continues to carry a poor prognosis. The role of 
palliative chemotherapy is therefore of utmost imporr
tance.
Single agents with activity in advanced gastric canr
cer include 5rfluorouracil (5FU), cisplatin, the anr
thracyclines (doxorubicin and epirubicin), mitomycin 
C, and etoposide, with pooled response rates in the 
range of 10% to 20%.2 Various combinations of these 
agents have been tried to improve upon these response 
rates. These include 5FU, doxorubicin and mitomycin 
(FAM); 5FU, doxorubicin and highrdose methotrexr
ate (FAMTX); epirubicin, cisplatin and 5FU (ECF); 
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BACKGROUND: at present, there is no standard regimen for the treatment of gastroesophageal cancer. 
docetaxel, cisplatin and fluorouracil (dcf) has been shown to be an effective regimen; however, toxicity is an 
area of concern in the palliative case setting. capecitabine and oxaliplatin have been shown to be as effective as 
fluorouracil and cisplatin, respectively. to reduce the toxicity of dcf while maintaining efficacy, we conducted 
this study to evaluate the efficacy of docetaxel, oxaliplatin and capecitabine (doX) combination in advanced 
gastroesophageal cancer. 
METHODS: patients with histologically confirmed metastatic or locally advanced adenocarcinoma of the stom-
ach or gastroesophageal junction received docetaxel 25 mg/m2 and oxaliplatin 50 mg/m2 on days 1 and 8 with 
capecitabine 625 mg/m2 twice daily from day 1-14, in 21-day cycles. the primary endpoint was overall response 
rate (orr). 
RESULTS: of 21 patients, there were 16 males and 5 females with a median age of 57 years, range 37-80 years. 
the primary tumor was located at the gastroesophageal junction in 7 patients and in other parts of the stomach 
in the remaining 14 patients. one patient had locally advanced tumor without distant metastases and 20 patients 
presented with metastatic disease. Grade 3/4 toxicities included diarrhea (24%), hand-foot syndrome (5%) and 
febrile neutropenia (5%). the orr was 29%. the median survival was 8.4 months. at the time of analysis, 5 of the 
21 patients (24%) were alive. 
CONCLUSIONS: the doX combination is tolerable, active and a promising day-care regimen for advanced 
gastroesophageal cancer.
etoposide, leucovorin and 5FU (ELF). As compared to 
best supportive care (BSC), combination chemotherapy 
has yielded significantly superior overall survival (OS) 
rates.3 However, no single regimen has claimed precer
dence over the others, and currently there is no universal 
standard regimen for the treatment of gastroesophageal 
cancer.4 Thus, new treatment protocols are warranted to 
achieve better disease control while maintaining a tolerr
able toxicity profile.
The Vr325 trial, the largest international phase III 
trial, showed that adding docetaxel to cisplatin and 5FU 
improves the timertorprogression (TTP), survival, and 
response rate in gastric cancer patients, but resulted in 
increase in toxicity.5 Current reports suggest that subr
stituting capecitabine for 5FU, and oxaliplatin for cisr
platin, prolongs OS as well as improves safety, quality 
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of life (QOL) and efficacy.6
Oxaliplatin is a thirdrgeneration diaminocyclohexr
ane platinum compound, which is an alkylating agent 
inhibiting DNA replication by forming adducts ber
tween two adjacent guanines, or guanine and adenine 
molecules. Adducts of oxaliplatin appear to be more 
effective than cisplatin adducts with regard to the inr
hibition of DNA synthesis and it has a more favorable 
toxicity profile. Capecitabine is an oral fluoropyrimir
dine that is activated to 5FU preferentially in tumor 
tissue by a threerstep enzymatic conversion culminatr
ing with thymidine phosphorylase (TP).7 In phase III 
trials, efficacy data for capecitabine compared favorably 
with that of parenteral 5FU in the firstrline metastatic 
setting, and resulted in a consistently lower frequency of 
grade 3 or 4 toxic effects.8 Docetaxel has shown promisr
ing activity in gastric cancer, both as monotherapy and 
in combination with other agents.9 Moreover, docetaxel 
shows synergy with capecitabine, as it upregulates TP 
enzyme in tumor cells.
Encouraged by the high efficacy of DCF and the 
better safety profile of capecitabine and oxaliplatin 
when used in place of 5FU and cisplatin, respectively, 
we designed this study to test the safety and efficacy of 
the DOX combination.
PATIENTS AND METHODS
Eligibility criteria included a histologically confirmed 
metastatic or locally advanced (LA) adenocarcinoma 
of the stomach or gastroesophageal junction, an age 
18 of years or older, an Eastern Cooperative Oncology 
Group (ECOG) performance status <2, ≥1 unidimenr
sionally measurable lesion ≥1 cm in diameter detected 
by CT scan or MRI, no prior chemotherapy except in 
the adjuvant or neoadjuvant setting >6 months prior 
to study entry and adequate renal, hepatic and hemar
tologic function. Exclusion criteria included a second 
malignancy, uncontrolled infection, and neuropathy 
grade >1. Pregnant or lactating women were excluded. 
All patients gave informed consent prior to enrollment 
in the study.
Docetaxel was administered as 25 mg/m2 folr
lowed by oxaliplatin 50 mg/m2 on days 1 and 8, with 
capecitabine 625 mg/m2 twice daily from days 1 to 14, 
in 21rday cycles. Patients received standard hydration 
and premedication with corticosteroids and antiemetr
ics. Granulocyte colonyrstimulating factor (GrCSF) 
was used only as secondary prophylaxis once patients 
had febrile neutropenia or documented neutropenic 
infection. 
Toxicity was graded according to National Cancer 
Institute Common Toxicity Criteria (NCIrCTC, verr
sion 3.0). Depending on the severity of side effects, cher
motherapy was paused or the dose was reduced. A 20% 
dose reduction was required based on predefined criter
ria. Briefly, docetaxel was reduced by 20% in case of the 
following toxicities: grade 3 or 4 neutropenia lasting 
more than 7 days (or in presence of fever), second or 
third incidence of febrile neutropenia despite GrCSF 
support administered after the first occurrence. The 
capecitabine dose was reduced by 20% on occurrence 
of grade 3 or 4 diarrhea or hand/foot syndrome. The 
oxaliplatin dose was reduced by 20% in case of grade 
3 or 4 peripheral neuropathy. Patients were considered 
assessable for toxicity if they had received a minimum 
one cycle of treatment.
Before registration, a complete medical history was 
taken, tumorrrelated symptoms were recorded and 
a full body examination was performed. A complete 
blood cell count (CBC), blood chemistry analyses, 
electrocardiograph, measurement of creatinine clearr
ance and tumor assessment were carried out in all 
patients at study entry. Patients were assessed weekly 
for potential adverse events and diseaserrelated signs 
and symptoms. Response was evaluated after cycle 3 
and cycle 6 according to RECIST criteria.10 All par
tients completing a minimum of 3 cycles were eligible 
for efficacy evaluation. Treatment was continued until 
completion of 6 cycles, evidence of disease progression, 
or death or consent withdrawal, whichever occurred 
earlier. Patients who had ended treatment but had not 
experienced disease progression were observed every 8 
weeks until progressive disease developed using pertir
nent imaging studies, and every 3 months thereafter. 
Regardless of response, all patients were followed up 
until death. 
The primary end point was overall response rate 
(ORR). The primary efficacy end point was the comr
plete response (CR) rate. Patients were considered asr
sessable for response if they had received at least three 
cycles of treatment. Secondary end points included 
TTP, OS and toxicity. The TTP was determined from 
the day of enrollment to the date of any progression, 
death, or last contact. Patients who had not progressed 
at the time of the final analysis were censored at the 
date of their last tumor assessment. OS was calculated 
from the day of enrollment to death. Patients alive at 
the final survival analysis were censored using the last 
contact date. All treated patients were included in the 
toxicity analyses.
RESULTS
Twentyrone patients were enrolled between March 2007 
and February 2009. The primary tumor was located at 
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the gastroesophageal junction in 7 patients and in other 
parts of the stomach in the remaining 14 patients. One 
patient had locally advanced tumor without distant mer
tastases and 20 patients presented with metastatic disr
ease, with lymph nodes, the liver, peritoneum and lung 
as the predominant metastatic sites (Table 1).
In total, 91 cycles of DOX were administered, with 
a median of three cycles (range 2 to 6) per patient. The 
median duration of treatment was 12 weeks (range 1 to 
18). Dose reductions (including docetaxel in 1/21 par
tients [5%] and capecitabine in 6/21 patients [29%]) 
were due to febrile neutropenia in one patient (5%), 
grade 3/4 diarrhea in five patients (24%), and handrfoot 
syndrome in one patient (5%). At least one dose reducr
Table 1. patient and tumor characteristics at baseline.
   Characteristics
Number of 
patients *
(n = 21)
%
   Age (years)
      Median 57
      range 37-80
   Gender 
      Male 16 76
      Female 5 23
   ECOG performance status
      0 13 62
      1 8 38
   Site of primary tumor
      Stomach 14 67
      gastroesophageal junction 7 33
   Disease status
      locally advanced 1 5
      Metastatic 20 95
   Histology 
      adenocarcinoma 21 100
   Metastasis sites
      lymph node 13 62
      liver 6 29
      lung 2 10
     peritoneal carcinomatosis 12 57
     Other 2 10
* Unless otherwise indicated
Table 2. Hematologic and non-hematologic toxicities in 21 patients (national Cancer 
institute common toxicity criteria, version 3.0).
   Toxicity Grade 1-2 Grade 3-4 Total
   Hematologic
      anemia 5 (1) 0 (0) 5 (1)
      neutropenia 10 (2) 0 (0) 10 (2)
      Febrile neutropenia - 5 (1) 5 (1)
      Thrombocytopenia 19 (4) 0 (0) 19 (4)
   Non-hematologic
      diarrhea 29 (6) 24 (5) 52 (11)
      nausea 29 (6) 0 (0) 29 (6)
      emesis 29 (6) 0 (0) 29 (6)
      elevated alT/aST 5 (1) 0 (0) 5 (1)
      Hand foot syndrome 5 (1) 5 (1) 10 (2)
      Sensory neuropathy 10 (2) 0 (0) 10 (2)
Values aer percentages (number of patients)
tion was performed in 6/21 patients (29%) due to grade 
3/4 toxicity.
The median time until early treatment discontinuar
tion was 9 weeks (range 4 to 9). The main reason for 
therapy discontinuation was progressive disease (PD) 
(43%), followed by toxicity (5%) and consent withdrawr
al (5%). There were no treatmentrrelated deaths.
All 21 patients were assessable for toxicity. 
Hematologic and nonrhematologic adverse events are 
summarized in Table 2. Treatment was generally well 
tolerated, with severe adverse events occurring in 7/91 
cycles (8%). Overall, 6 patients (29%) experienced grade 
3/4 adverse events. The most frequent grade 3/4 her
matologic toxicity was febrile neutropenia, occurring in 
only 5% of patients and 1% of cycles. The most frequent 
grade 3/4 nonrhematologic toxicities possibly or probr
ably related to study treatment were diarrhea (24% of 
patients, 5% of cycles) and handrfoot syndrome (5% of 
patients, 1% of cycles). Grade 1r2 toxicities were manr
aged with supportive care (GrCSF, erythropoietin, blood 
transfusion, antiemetics). For grade 3r4 toxicity, the dose 
of docetaxel and capecitabine was reduced by 20%.
Nineteen patients (90%) were assessable for response 
according to RECIST criteria. Two patients were not 
assessable (one patient was lost to followrup and one 
patient stopped therapy after the first cycle due to toxr
icity), but are included in the response analysis (Table 
3). The overall response rate (ORR; complete response 
+ partial response) was 29%. The median TTP was 4.9 
months (Figure 1). The median OS for 19 patients was 
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Table 3. antitumor efficacy.
   Response Number of patients (n=21) %
   Overall response rate 6 29
   Complete response 3 14
   partial response 3 14
   Stable disease  4 19
   progressive disease 9 43
   not assessable 2 10
8.4 months (Figure 2). At the time of the analysis, 5 of 
the 21 patients enrolled (24%) were alive.
DISCUSSION
There is currently no universal standard regimen for the 
treatment of gastroesophageal cancer. Metaranalysis has 
shown the value of combination chemotherapy regimens 
compared with single agents.11 The addition of docetaxel 
to cisplatinr5FU resulted in increases in the TTP, OS and 
QOL, although at the expense of increased toxicity. The 
V325 study group performed this phase III, randomized 
trial comparing DCF with the reference regimen CF.5 
ORR was higher with DCF (37% vs 25%), which estabr
lished a role for docetaxel in the treatment of advanced 
gastroesophageal cancer. However, DCF has significant 
toxicity and tolerability issues, with greater grade III/IV 
neutropenia (82% vs 57%), leucopenia (65% vs. 31%) 
and diarrhea (19% vs. 8%). About 50% of patients on the 
DCF arm could not complete the scheduled treatment 
due to toxicity or unwillingness to continue treatment.
Cunningham et al, in a randomized, phase 3 study, 
showed that for advanced gastroesophageal cancer, oral 
capecitabine and oxaliplatin are not inferior to infused 
fluorouracil and cisplatin, respectively, with respect to 
OS.12 Response rates were highest in the epirubicin and 
oxaliplatin plus capecitabine (EOX) group, followed by 
the epirubicin and cisplatin plus capecitabine (ECX) 
group. Survival analysis found that the regimen of EOX 
was superior to ECF with a median survival of 11.2 
months versus 9.9 months. EOX had significantly less 
neutropenia and renal insufficiency when compared with 
ECF, but more peripheral neuropathy and diarrhea.
With this background, we made an effort to modify 
the efficacious, albeit toxic DCF regimen, by replacing 
cisplatin with oxaliplatin and 5FU with capecitabine, 
to make it more tolerable and easier to administer while 
maintaining efficacy. The Brown University Oncology 
Group conducted a phase 1 trial to study this combinar
tion of DOX in patients with metastatic esophageal and 
gastric cancer.13 They suggested the regimen of docetaxel 
30 mg/m2 and oxaliplatin 50 mg/m2 day 1 and 8 with 
capecitabine 750 mg/m2 twice daily for 10 days in 21rday 
cycles. The study enrolled 16 patients with very heteroger
neous characteristics: 8 patients had esophageal cancers, 
of which 2 had squamous histology and 6 were adenor
carcinomas; 8 patients had gastric adenocarcinomas. 
Our study consisted of a more homogenous patient 
population, consisting only of gastric and gastroesophr
ageal junction adenocarcinomas. The drug regimen in 
our study was modified slightly for better tolerability 
and consisted of docetaxel 25 mg/m2 and oxaliplatin 
50 mg/m2 given on days 1 and 8, with capecitabine 625 
Figure 1. Kaplan-Meier curve for time-to-progression.
Figure 2. Kaplan-Meier curve for overall survival.
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mg/m2 twice daily from days 1 to 14 in 21rday cycles.
The DOX regimen used the promising activity of 
all 3 agents against gastroesophageal cancer. We used 
a lower dose of docetaxel compared to the V325 trial, 
and also administered it on a weekly schedule. This 
resulted in significantly less hematologic toxicity and 
necessitated dose reduction in only one (5%) patient, 
who developed febrile neutropenia. There were no der
lays in chemotherapy related to toxicity in this study, 
and a very low rate of neutropenia was noted despite 
no prophylactic use of growth factors. In addition, the 
reduced nausea and nephrotoxicity of oxaliplatin comr
pared to cisplatin, combined with its activity, makes it 
an excellent option for inclusion in this combination 
regimen. Also, replacing 5FU with oral capecitabine 
reduces the hospital stay for prolonged infusions and 
enables easy administration of this regimen in a dayr
care setting. 
In this single center experience, we present data for 
the DOX combination in advanced gastric and gastror
esophageal cancer. The regimen was well tolerated with 
a manageable toxicity profile and acceptable efficacy. 
The most common toxicity in this study was diarrhea 
related to capecitabine. In the palliative setting of inr
operable gastric and gastroesophageal cancer, a chemor
therapy regimen that is convenient, less toxic and at the 
same time efficacious, is the need of the day. Therefore, 
the DOX regimen is a promising dayrcare regimen for 
advanced gastroesophageal cancer.
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